Clinical Trial

Physician- and Patient-based Barriers to NGS Testing

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-09-30; most recent amendment 2026-01-30.
Status change: Not Yet Recruiting → Recruiting 2026-01-30
Trial Details
NCT Number NCT07209176
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Pfizer
Conditions Metastatic Prostate Cancer
Enrollment 256 participants
Start Date 2026-01-06
Primary Completion 2027-09-06 (estimated)
Study Completion 2027-09-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-03